Search the Studies

22 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001696-CSurveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)Recruitment has not started3-120 YearsNCI Neurofibromatosis
000696-CA Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform NeurofibrParticipants currently recruited/enrolled18-120 YearsNCI Neurofibromatosis
000657-CAcceptance and Commitment Therapy for Caregivers of Children with a RASopathy: An Internal Pilot Feasibility Study and Follow-up Phase III Randomized Controlled TrialParticipants currently recruited/enrolled18-125 YearsNCI Neurofibromatosis
21-C-0011A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical NeurofibromasParticipants currently recruited/enrolled12-125 YearsNCI Neurofibromatosis
19-C-0061A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorsCompleted Study; data analyses ongoing12-125 YearsNCI Neurofibromatosis
18-C-0102Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)Completed Study; data analyses ongoing18-125 YearsNCI Neurofibromatosis
18-C-0093Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment TrialsCompleted Study; data analyses ongoing3-125 YearsNCI Neurofibromatosis
16-C-0043Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNo longer recruiting/follow-up only18-125 YearsNCI Neurofibromatosis
15-C-0195Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)Participants currently recruited/enrolled5-125 YearsNCI Neurofibromatosis
15-C-0142Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical TrialCompleted Study; data analyses ongoing16-59 YearsNCI Neurofibromatosis
15-C-0093Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCTParticipants currently recruited/enrolled3-35 YearsNCI Neurofibromatosis
15-C-0019The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1Completed Study; data analyses ongoing4-99 YearsNCI Neurofibromatosis
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI Neurofibromatosis
12-C-0206Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive StudyCompleted Study; data analyses ongoing18-125 YearsNCI Neurofibromatosis
12-C-0160Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their ParentsCompleted Study; data analyses ongoing18-125 YearsNCI Neurofibromatosis
11-C-0161A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)No longer recruiting/follow-up only2-18 YearsNCI Neurofibromatosis
08-N-0044A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2).Participants currently recruited/enrolled8-75 YearsNINDSNeurofibromatosis
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI Neurofibromatosis
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI Neurofibromatosis
07-C-0110Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved ProtocolsEnrolling by Invitation0-125 YearsNCI Neurofibromatosis
06-C-0134Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1Completed Study; data analyses ongoing20-99 YearsNCI Neurofibromatosis
05-C-0152Variation in Gene Expression in Neurofibromatosis Type 1Completed Study; data analyses ongoing2-100 YearsNCI Neurofibromatosis
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®